Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC)-Reference-Cited by-同舟云学术

Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC)

Published:2021-11 Issue: Volume:122 Page:105546
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Shu Lihua,Wang Dongsheng,Nannapaneni Sreenivas,Sun Youzhi,Griffith Christopher C.,Wang Xu,Chen Zhengjia,Patel Mihir,El-Deiry Mark,Shin Dong M,Chen Zhuo G,Saba Nabil F

Funder

Emory University

Emory University School of Medicine

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference43 articles.

1. Global cancer statistics, 2002;Parkin;CA Cancer J. Clin.,2005

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

3. Cancer statistics, 2012;Siegel;CA. Cancer J. Clin.,2012

4. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019

5. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm;Bauml;Phase II Study. J. Clin. Oncol.,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma;Frontiers in Pharmacology;2024-01-19

2. Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma;Targeted Oncology;2023-09

3. Combination Therapy as a Promising Way to Fight Oral Cancer;Pharmaceutics;2023-06-04

4. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?;Current Opinion in Oncology;2023-03-17